{"id":497616,"date":"2024-01-27T02:03:28","date_gmt":"2024-01-27T07:03:28","guid":{"rendered":"https:\/\/platohealth.ai\/wave-neuroscience-acquires-assets-of-neosync-medical-device-news-magazine\/"},"modified":"2024-01-27T08:50:17","modified_gmt":"2024-01-27T13:50:17","slug":"wave-neuroscience-acquires-assets-of-neosync-medical-device-news-magazine","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/wave-neuroscience-acquires-assets-of-neosync-medical-device-news-magazine\/","title":{"rendered":"Wave Neuroscience Acquires Assets Of NeoSync – Medical Device News Magazine","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n
\n

Wave Neuroscience reported today (February 26, 2020), among the assets acquired are 19 issued and four pending patents which will be added to Wave\u2019s existing portfolio, strengthening Wave\u2019s position in EEG and EEG\/EKG guided TMS.<\/h4>\n

In addition, Wave Neuroscience has acquired the Neuro-EEG Synchronization Therapy (NEST\u00ae) system developed and tested by NeoSync. The NEST\u00ae device is a technologically advanced helmet design that imparts stimulation at precise frequencies to the patient\u2019s brain and has shown promising results in clinical trials. Wave will work towards proving the safety and efficacy of the NEST\u00ae platform, incorporating its algorithms and moving to eventual FDA clearance for this novel, portable, in-home technology.<\/p>\n

\u201cWe are very excited to add NeoSync\u2019s complementary IP and products to our rapidly growing suite of technologies,\u201d said Fred Walke, CEO of Wave. \u201cThis acquisition further exemplifies our commitment to creating and optimizing what others are now realizing is possible: targeted and personalized neuromodulation that honors an individual\u2019s unique physiology more closely than the one-size-fits-all approach commonly used today. We find especially compelling the fact that the NEST\u00ae is designed for eventual home-use. Once commercially available, the NEST\u00ae will provide wide accessibility to this groundbreaking treatment, improving the quality of life for many.\u201d<\/p>\n

Kate Rumrill, NeoSync\u2019s president and CEO said, \u201cWe are pleased Wave is taking over the stewardship of the NeoSync technology assets and heartened by its commitment to maximize the tremendous potential of the NEST\u00ae system. We look forward to seeing the technology reaching its full capabilities, providing broader access to patients in need.\u201d<\/p>\n

Wave Neuroscience is a developer of noninvasive technology aimed at addressing neurological disorders and enhancing cognitive brain function through Transcranial Magnetic Stimulation. <\/span><\/p>\n<\/div>\n